Playtika (PLTK) Q3 2025 Earnings Call Transcript

Israeli defense company Elbit reports a $32 billion order backlog, equivalent to 4.4% of Israel's GDP. The backlog is driven by demand for defense technologies amid global conflicts. Elbit plans to expand production and hire 2,000 more employees. Additionally, Israeli tech startups have seen significant foreign investments, including acquisitions by Tencent, Cisco, and Instacart. Israel's economy is projected to grow 4.4% to 5.6% in 2027, with stable inflation and a narrowing fiscal deficit.

Playtika Holding Corp. (Nasdaq: PLTK) reported Q2 2026 revenue of NIS 731.1 million (+5% YoY) and net profit of $48.0 million, after a prior-quarter loss. Operating profit rose to $134.6 million (+23%). The company warned H2 results may land near the low end of 2026 guidance, citing weaker consumer spending and lower marketing. Shares fell to $3.29 (-15.4% intraday).

Playtika Holding Corp. (PLTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Playtika Holding Corp. Reports Q2 2026 Financial Results Revenue of $731.1 million and Direct-to-Consumer (“DTC”) Revenue of $286.9 million Revenue Decreased (1.8)% Sequentially and Increased 5.0% Year Over Year DTC Platforms Revenue Decreased (1.7)% Sequentially and

Playtika is reportedly in talks to sell its SuperPlay unit to Tencent for a valuation of $1.0 billion to $1.5 billion, according to Calcalist. Playtika bought SuperPlay in 2024 for $700 million in cash plus performance-based payments up to $1.25 billion. If completed, the deal could be a sizable return for Playtika.

Microsoft (MSFT) received a BUY rating and $600 price target from 24/7 Wall St., citing 43% Azure growth and a $678B commercial RPO backlog. The stock is up 27.81% over the past month and 3.29% year-to-date, with Q4 FY26 revenue of $90.01B and non-GAAP EPS of $4.74. The target implies 18.9% upside, potentially pushing market cap to $5T. Bulls highlight demand outpacing supply, while bears note capital intensity and declining PC revenue.

Eli Lilly and Company's Kenosha facility, acquired in 2024, is part of a $4 billion investment in Wisconsin for injectable medicine production. The site, which received FDA approval in 18 months, is producing drugs like Zepbound and Mounjaro. The facility is expected to support 750 jobs and has attracted attention due to its strategic location and skilled workforce. Wisconsin has also joined a lawsuit against the Trump administration's family planning funding rules. The state collected $450.8 mi